drugset / Trial / NCT02705547
Rosuvastatin (Crestor) in Friedreich Ataxia
Phase 0
Completed
12 enrolled
Children's Hospital of Philadelphia
Friedreich's Ataxia Research Alliance · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is an exploratory open-label clinical trial of Rosuvastatin in patients with Friedreich ataxia (FRDA). This is an outpatient trial with the goal of enrolling 10 evaluable adults with genetically confirmed FRDA who are between the ages of 18-65. Subjects will receive 10mg of oral Rosuvastatin daily for three months.
Timeline
- Start
- 2016-05
- Primary completion
- 2017-08-04
- Completion
- 2017-08-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rosuvastatin | Small molecule | 10 mg | Oral |